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Aim/Introduction 
Active surveillance (AS) is currently the preferred initial option for patients with low risk 
prostate cancer (PC). AS requires patients to undergo regular office visits with periodic testing. 
We measured patient compliance to NCCN guidelines for AS through review of medical record 
abstractions.  
 
Methods 
White and Black patients (n=221) with newly diagnosed low-risk PC on AS identified through a 
population-based cancer registry were surveyed at baseline (4 months after diagnosis) and at 2 
year follow-up. 186 medical records reviewed and confirmed the AS protocol and compliance. 
Patient self-reported data were then compared with medical records data.  
 
Results 
Of the 186 patients who initially on AS, 151 remained on AS at 2 year follow-up. Overall, 55.2% 
(n=90) were guideline-concordant of having at least three PSA tests and one prostate biopsy 
during 2 year follow-up. Patients more likely guideline-concordant for PSA testing than 
guideline-concordant with prostate biopsy (76.7% vs. 66.9 %, respectively).  
 
Discussion 
Majority of patients on AS in this sample follow practice guidelines, but there is significant 
variation in the proportion of men on AS  that meet guideline recommendations for follow-up 
PSA testing and repeat biopsy.  These data highlight the need for further patients and providers 
education that emphasize the need of repeated testing including prostate biopsies to ensure safety 
of AS.  
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